About NovaCap
NovaCap is a company based in Ecully (France) founded in 2003 was acquired by Eurazeo in April 2016. NovaCap has completed 3 acquisitions, including Chemoxy, ID Bio and PCI Synthesis. NovaCap operates in a competitive market with competitors including Laurus Labs, SeQuent, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
- Headquarter Ecully, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NovaCap
Detailed funding history for NovaCap
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in NovaCap
NovaCap has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eurazeo and Ardian.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and debt investments are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
Private investment firm specializing in markets and partnerships.
|
Locked | Locked | Locked |
Investor details for NovaCap
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NovaCap
NovaCap has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Chemoxy, ID Bio and PCI Synthesis.
Investment portfolio details for NovaCap
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
API manufacturing, custom synthesis, and scale-up services are provided.
|
Locked | Locked | 1996 | Locked | |
|
CDMO focused on manufacturing of API products for biopharma sector
|
Locked | Locked | 1993 | Locked | |
|
Contract manufacturing of chemical intermediates is conducted.
|
Locked | Locked | 1868 | Locked |
Complete acquisition details for NovaCap
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - NovaCap
Detailed financials for NovaCap
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novacap Comparisons
Peer comparison for NovaCap
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NovaCap
NovaCap operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, SeQuent, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
Custom chemical development and manufacturing services are offered for pharmaceuticals.
|
Detailed competitors of NovaCap
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novacap
Complete news archive for NovaCap
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovaCap
NovaCap was founded in 2003.
NovaCap is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
Pierre Luzeau is the current CEO of NovaCap.
Founded in 2003 and based in Ecully, France, APIs and pharmaceutical intermediates are developed and manufactured. Key products encompass salicylic acid, aspirin, paracetamol, and compounds for gastrointestinal, cardiovascular, analgesic, and steroid uses. Custom research, innovation, development, and manufacturing services are provided within the pharmaceutical sector. Operations focus on supporting global supply needs for these materials.
NovaCap's top competitors include Laurus Labs, Symbiotec and Divis Laboratories.
NovaCap has made 3 acquisitions, including Chemoxy, ID Bio, and PCI Synthesis.